Zobrazeno 1 - 10
of 16
pro vyhledávání: '"John P. Sims"'
Autor:
Shoichiro Sato, Naohisa Hatakeyama, Shinji Fujikoshi, Sadao Katayama, Hideaki Katagiri, John R. Sims
Publikováno v:
Neurology and Therapy, Vol 13, Iss 3, Pp 677-695 (2024)
Abstract Introduction Donanemab, a monoclonal antibody directed against an insoluble, modified, N-terminal truncated form of amyloid beta, demonstrated efficacy and safety in patients with early, symptomatic Alzheimer’s disease (AD) in the phase 3
Externí odkaz:
https://doaj.org/article/be20011aa132481f9552d79d68110fd0
Autor:
Sergey Shcherbinin, Amanda Morris, Ixavier A. Higgins, Ilke Tunali, Ming Lu, Carmen Deveau, Sudeepti Southekal, Vikas Kotari, Cynthia D. Evans, Anupa K. Arora, Emily C. Collins, Michael Pontecorvo, Mark A. Mintun, John R. Sims
Publikováno v:
Alzheimer’s & Dementia: Translational Research & Clinical Interventions, Vol 9, Iss 3, Pp n/a-n/a (2023)
Abstract INTRODUCTION Alzheimer's disease (AD) is characterized by the presence of both amyloid and tau pathology. In vivo diagnosis can be made with amyloid and tau positron emission tomography (PET) imaging. Emergent evidence supports that amyloid
Externí odkaz:
https://doaj.org/article/ab842ff432c0473d94e3cf6ace32976f
Autor:
Ivelina Gueorguieva, Brian A. Willis, Laiyi Chua, Kay Chow, C. Steven Ernest II, Jian Wang, Sergey Shcherbinin, John R. Sims, Emmanuel Chigutsa
Publikováno v:
Alzheimer’s & Dementia: Translational Research & Clinical Interventions, Vol 9, Iss 2, Pp n/a-n/a (2023)
Abstract INTRODUCTION Donanemab is an amyloid‐targeting therapy that specifically targets brain amyloid plaques. The objective of these analyses was to characterize the relationship of donanemab exposure with plasma biomarkers and clinical efficacy
Externí odkaz:
https://doaj.org/article/46f199eccdf94cd1a9b67b5c825effb4
Autor:
Shorena Janelidze, Erik Stomrud, Ruben Smith, Sebastian Palmqvist, Niklas Mattsson, David C. Airey, Nicholas K. Proctor, Xiyun Chai, Sergey Shcherbinin, John R. Sims, Gallen Triana-Baltzer, Clara Theunis, Randy Slemmon, Marc Mercken, Hartmuth Kolb, Jeffrey L. Dage, Oskar Hansson
Publikováno v:
Nature Communications, Vol 11, Iss 1, Pp 1-12 (2020)
Cerebrospinal fluid (CSF) p-tau181 (tau phosphorylated at threonine 181) is an established biomarker of Alzheimer’s disease (AD) reflecting abnormal tau metabolism in the AD brain. Here the authors demonstrate that CSF p-tau217 shows better perform
Externí odkaz:
https://doaj.org/article/e021f91d669745fe90cd9b4d834f6303
Publikováno v:
Alzheimer’s & Dementia: Translational Research & Clinical Interventions, Vol 8, Iss 1, Pp n/a-n/a (2022)
Abstract Introduction The Integrated Alzheimer's Disease Rating Scale (iADRS) has been used to detect differences in disease progression in early Alzheimer's disease (AD). The objectives of this study were to enhance understanding of iADRS point chan
Externí odkaz:
https://doaj.org/article/f1475d039f7948df85c74296ac37d6f8
Autor:
Diana Otero Svaldi, Ixavier A. Higgins, Karen C. Holdridge, Roy Yaari, Michael Case, Luc Bracoud, David Scott, Sergey Shcherbinin, John R. Sims
Publikováno v:
Alzheimer’s & Dementia: Translational Research & Clinical Interventions, Vol 8, Iss 1, Pp n/a-n/a (2022)
Abstract Introduction Solanezumab is a monoclonal antibody that preferentially binds soluble amyloid beta and promotes its clearance from the brain. The aim of this post hoc analysis was to assess the effect of low‐dose solanezumab (400 mg) on glob
Externí odkaz:
https://doaj.org/article/c88699e26d684a68be60ce2fde940679
Autor:
Natally Horvat, Jose de Arimateia B. Araujo-Filho, Antonildes N. Assuncao-Jr, Felipe Augusto de M. Machado, John A. Sims, Camila Carlos Tavares Rocha, Brunna Clemente Oliveira, Joao Vicente Horvat, Claudia Maccali, Anna Luísa Boschiroli Lamanna Puga, Aline Lopes Chagas, Marcos Roberto Menezes, Giovanni Guido Cerri
Publikováno v:
Clinics, Vol 76 (2021)
OBJECTIVES: To investigate whether quantitative textural features, extracted from pretreatment MRI, can predict sustained complete response to radiofrequency ablation (RFA) in patients with hepatocellular carcinoma (HCC). METHODS: In this IRB-approve
Externí odkaz:
https://doaj.org/article/b73645a48718411b83f2673e88ac0224
Autor:
Jennifer A. Zimmer, Sergey Shcherbinin, Michael D. Devous Sr., Sonja M. Bragg, Katherine J. Selzler, Alette M. Wessels, Craig Shering, Jamie Mullen, John Landry, Scott W. Andersen, AnnCatherine M. Downing, Adam S. Fleisher, Diana Otero Svaldi, John R. Sims
Publikováno v:
Alzheimer’s & Dementia: Translational Research & Clinical Interventions, Vol 7, Iss 1, Pp n/a-n/a (2021)
Abstract Introduction Lanabecestat, a beta‐site amyloid precursor protein‐cleaving enzyme 1 (BACE1) inhibitor, was investigated as a potential Alzheimer's disease (AD)‐modifying treatment. As previously reported, amyloid beta (Aβ) neuritic pla
Externí odkaz:
https://doaj.org/article/b11b2d19d9184e3eb390acfbb6efc91b
Autor:
Stephen Loucian Lowe, Brian A. Willis, Anne Hawdon, Fanni Natanegara, Laiyi Chua, Joanne Foster, Sergey Shcherbinin, Paul Ardayfio, John R. Sims
Publikováno v:
Alzheimer’s & Dementia: Translational Research & Clinical Interventions, Vol 7, Iss 1, Pp n/a-n/a (2021)
Abstract Introduction This study explored the safety and tolerability features of donanemab (LY3002813) in patients with mild cognitive impairment due to Alzheimer's disease (AD) or mild to moderate AD dementia. Methods Patients with AD were enrolled
Externí odkaz:
https://doaj.org/article/fc3a8ec9b31144a59529adb9909dc026
Autor:
Peter Filip, Joshua Zeiger, Mykayla Sandler, Roshanak Alialy, John R. Sims, Azita S. Khorsandi, Raymond L. Chai
Publikováno v:
Otolaryngology Case Reports, Vol 15, Iss , Pp - (2020)
Objectives: Hypopharyngeal liposarcomas are rare tumors of the head and neck with only scattered case reports in the literature. They are predominantly seen in male patients with a propensity to occur during the 5th decade of life. Patients typically
Externí odkaz:
https://doaj.org/article/14bd2b16d6864f75a9e61c14e7b4692c